Lipids & Atherosclerosis

The Clinician’s Handbook- Dyslipidaemia and Atherosclerosis translates recent guidelines for treatment of dyslipidaemia in cardiovascular prevention to an easily accessible and practically oriented handbook to be used in daily clinical practice. The Handbook is based on the EAS/ESC Joint Guidelines for Management of Dyslipidaemia, 2016, and is endorsed by EAS and ESC.

To give a good background for the practical use of guidelines this handbook gives a brief summary of lipoprotein metabolism and the role of lipids and lipoproteins in the pathophysiology of atherosclerosis.
In a comprehensive way the Handbook discusses which lipids should be analysed for CVD risk estimation. Furthermore the different forms of hyperlipidaemia and their pathophysiological background is described. The role of lifestyle and genetic background for the development of dyslipidaemia is emphasized. The content also summarizes the lifestyle and pharmacological options for treatment and the treatment targets for different groups of patients.

This updated edition of the Handbook includes the changes made in the 2016 version of the EAS/ESC guidelines. This for example includes the changed position of ezetimibe after the IMPROVE-IT trial, the new developments of the PCSK9-inhibitors and recent advances in the management of familial hypercholesterlaemia. The Handbook also discusses the importance of treatment targets and the scientific background for lower targets in selected groups of patients.
Authored by leading experts in the field, the Handbook should be an invaluable and accessible resource for both primary and secondary care clinicians.

The development of the handbook was supported by an Unrestricted Educational Grant from SANOFI and REGENERON.